FDA Sticks Breakthrough Tag on GlaxoSmithKline's Blood Cancer Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate. Source: BioSpace You Might Also Like ObsEva Reports Second Quarter 2017 Financial Results And Provides Business Update August 15, 2017 Billionaire Businessman Looking to Take Stake in Debt-Ridden Teva November 5, 2017 Array BioPharma Slaps $192M Lawsuit on AstraZeneca Over Cancer Drug Royalties February 1, 2018
